当前位置:首页 > 报告详情

Revvity-2024JPM_Healthcareconference.pdf

上传人: 2*** 编号:151900 2024-01-05 17页 1.61MB

1、J.P.Morgan42ndHealthcare ConferencePrahlad SinghChief Executive OfficerJanuary 9,2024Safe HarborThis presentation contains forward-looking statements which are statements relating to future events.These statements include those relating to estimates and projections of future earnings per share,cash

2、flow and revenue growth and other financial results,developments relating to our customers and end-markets,and plans concerning business development opportunities.Words such as believes,intends,anticipates,plans,expects,projects,forecasts,will and similar expressions,and references to guidance,are i

3、ntended to identify forward-looking statements.Such statements are based on managements current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct.A number of important risk factors could cause actual results to differ materially

4、 from the results described,implied or projected in any forward-looking statements.A detailed description of these risk factors can be found under the caption“Risk Factors”in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission.We disclai

5、m any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.Guidance for future periods is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the un

6、predictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures.The timing and amounts of such events and items could be material to the Companys results prepared in accordance with GAAP.2Revolutionizing human health at an accelerated rev spee

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
Revvity是一家致力于人类健康未来发展的公司,首席执行官Prahlad Singh在2024年1月9日的J.P. Morgan第42届医疗保健会议上发表了讲话。该公司通过科学创新,推动人类健康领域的变革,其业务分为两大块:诊断和生命科学。生命科学领域,Revvity以约80%的比重提供消耗品、服务和软件,以约20%的比重提供仪器。诊断领域,2023年的预期收入约为14亿美元,总 addressable market 约为350亿美元。Revvity的产品和服务涵盖了新生儿筛查、母胎健康、传染病诊断等多个领域。公司预计,2023年其生命科学收入将达到27亿美元,诊断收入将达到7亿美元。在中国,Revvity的业务增长主要依赖于免疫诊断和消耗品的销售。未来,Revvity将继续推动创新,提高效率,战略性地部署资本,以实现有机和无机增长。
"Revvity如何通过科学创新推动人类健康革命?" "该公司在中国市场的独特表现背后有哪些策略?" "Revvity在2024年的发展重点是什么?"
客服
商务合作
小程序
服务号
折叠